CCP
TCRT icon

Corient Capital Partners’s Alaunos Therapeutics TCRT Stock Holding History

Corient Capital Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-72
Closed -$12K – 766
2021
Q4 		$12K Sell
72
-239
-77% -$52.5K ﹤0.01% 718
2021
Q3 		$85K Hold
311
– – 0.01% 684
2021
Q2 		$123K Buy
311
+96
+45% +$44.8K 0.01% 655
2021
Q1 		$116K Hold
215
– – 0.01% 598
2020
Q4 		$82K Buy
+215
New +$85.5K 0.01% 522

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corient Capital Partners's TCRT Position: Q1 2022 in Review

Corient Capital Partners sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 72 shares — an estimated $12K sold.

Corient Capital Partners first reported a position in TCRT in Q4 2020 and held it in 5 quarters. The position peaked at $123K in Q2 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • Corient Capital Partners reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Corient Capital Partners sold 72 Alaunos Therapeutics shares in Q1 2022, an estimated $12K.
  • Corient Capital Partners first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 5 quarters.
  • Corient Capital Partners's Alaunos Therapeutics position peaked at $123K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.